
|Videos|June 9, 2020
SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?
Author(s)Grant M. Gallagher
Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Population Study Confirms Rare Risk of Acute Respiratory Failure with TMP-SMX
2
Early 2025 Influenza Vaccination Trends Following Prior Season and H3N2 Start
3
Top Infectious Disease News Stories Week of November 29 - December 5
4
ACIP Votes on Hepatitis B Vaccine Marks More Confusion, No Supportive Safety Data, and Uncertainty of Public Health Policy
5























































































































































































































































































